Love Employee
Pyxis Oncology (NASDAQ:PYXS) is down ~38% in after-hours trading Wednesday after posting preliminary phase 1 data on PYX-201, an antibody-drug conjugate for solid tumors.
The data presented was in six heavily pre-treated individuals with head and neck squamous cell carcinoma. While